The short answer
Check grapefruit with the cancer team before using it with zanubrutinib. The oral product information identifies it as an enzyme-interaction concern; a few hours of separation is not a validated substitute for review.
What this answer covers
Oral zanubrutinib with grapefruit fruit or juice. Concentrated extracts, seed products and isolated synephrine are not assumed equivalent.
- Supplement or preparation
- Citrus paradisi
- Medication ingredient
- zanubrutinib
Check the prescribed treatment
This review concerns oral zanubrutinib in BRUKINSA capsules or tablets for selected blood cancers. Follow the exact product’s instructions and blood-count monitoring plan. The medicine can cause bleeding, but a drug warning alone does not prove that every supplement adds to that risk.
Why this fruit is singled out
The oral capsule product information names grapefruit and Seville oranges among products that can inhibit CYP3A. Inhibition can raise zanubrutinib exposure. That supports a specific precaution, but does not provide a measured interaction size for your usual serving or a supplement extract.
Drug studies do not establish fruit-dose equivalence
A volunteer study confirmed that strong drug inhibitors and inducers changed zanubrutinib exposure. It used itraconazole and rifampin, with carefully selected zanubrutinib doses. Those results cannot be assigned to grapefruit, Seville orange or a particular fruit extract.
Confirm the product before changing treatment
Describe the fruit, juice or supplement to the pharmacist, including how much and how often you use it. Do not transfer this advice to every citrus fruit, seed extract or isolated bitter-orange constituent. The team should decide whether to avoid the product; do not adjust zanubrutinib or rely on a dose gap.
Evidence and practical considerations
Absorption & effectiveness
Exact product information names the fruit/juice concern, supporting a conditional increased-exposure precaution rather than universal extract equivalence.
- Exact scope
- Oral zanubrutinib with grapefruit fruit or juice. Concentrated extracts, seed products and isolated synephrine are not assumed equivalent. with RxNorm 2262435 IN zanubrutinib. Exact current oral product: BRUKINSA oral zanubrutinib capsules and tablets. Salt, formulation and regimen distinctions explicit.
- Medication form and route
- Oral
What remains uncertain
- Named fruit/juice precaution in exact oral capsule information; no measured botanical PK trial or blanket plant-part equivalence. Current US label covers capsules/tablets but does not independently name these foods.
Factors that may matter: Exact oral formulation and supplement preparation; Drug exposure versus clinical outcomes; Dose and duration; Platelet count and neurological symptoms.
Read the supporting source summaries
Source 1: Current original prescribing information
dailymed.nlm.nih.gov · Source check Sep 11, 2026
Population: Patients prescribed the exact oral formulation.
Bleeding and cytopenia warnings; CYP3A inhibitor/inducer effects. Named citrus guidance separately sourced to capsule information.
How this applies: RxNorm 2262435 IN zanubrutinib. Exact current oral product: BRUKINSA oral zanubrutinib capsules and tablets. Salt, formulation and regimen distinctions explicit.
Exact product source, not a direct study of every supplement. Population, active metabolites and formulation scope retained.
Source 2: Current original product information
medicines.org.uk · Source check Sep 11, 2026
Population: Patients prescribed oral capsules.
Names grapefruit and Seville oranges as moderate CYP3A inhibitor concerns; use cautiously and review treatment.
How this applies: Exact drug named-citrus precaution.
Not every extract, seed, synephrine isolate or direct citrus PK trial; clinician dose management is product-specific.
Source 3: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 11, 2026
Population: Healthy Asian and non-Asian adults.
Strong induction decreased exposure; strong inhibition increased exposure.
How this applies: Exact preparation/population/endpoints only; applicability to zanubrutinib independently assessed.
Original full body; distinct doses selected for interaction experiments, not citrus products or transferable botanical effect size.
Source 4: Medication terminology
rxnav.nlm.nih.gov · Source check Sep 11, 2026
Population: Terminology.
zanubrutinib is IN.
How this applies: Exact ingredient.
Not clinical evidence.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Sources checked and article drafted. |
Article revision: 4584cc77772a57d0
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.